BACKGROUND AND OBJECTIVES:Delayed graft function is related to ischemia-reperfusion injury and may be complement dependent. We previously reported from a randomized, placebo-controlled trial that treatment with C1 esterase inhibitor was associated with a shorter duration of delayed graft function and higher eGFR at 1 year. Here, we report longer-term outcomes from this trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a post hoc analysis of a phase 1/2, randomized, controlled trial enrolling 70 recipients of deceased donor kidney transplants at risk for delayed graft function (NCT02134314). Subjects were randomized to receive C1 esterase inhibitor 50 U/kg (n=35) or placebo (n=35) intraoperatively and at 24 hours. The cumulative incidence functions method was used to compare graft failure and death over 3.5 years. eGFR slopes were compared using a linear mixed effects model. RESULTS: Three deaths occurred among C1 esterase inhibitor-treated patients compared with none receiving placebo. Seven graft failures developed in the placebo group compared with one among C1 esterase inhibitor-treated recipients; the cumulative incidence of graft failure was lower over 3.5 years among C1 esterase inhibitor-treated recipients compared with placebo (P=0.03). Although no difference in eGFR slopes was observed between groups (P for group-time interaction =0.12), eGFR declined in placebo-treated recipients (-4 ml/min per 1.73 m2 per year; 95% confidence interval, -8 to -0.1) but was stable in C1 esterase inhibitor-treated patients (eGFR slope: 0.5 ml/min per 1.73 m2 per year; 95% confidence interval, -4 to 5). At 3.5 years, eGFR was 56 ml/min per 1.73 m2 (95% confidence interval, 42 to 70) in the C1 esterase inhibitor group versus 35 ml/min per 1.73 m2 (95% confidence interval, 21 to 48) in the placebo group, with an estimated mean eGFR difference of 21 ml/min per 1.73 m2 (95% confidence interval, 2 to 41 ml/min per 1.73 m2). CONCLUSIONS: Treatment of patients at risk for ischemia-reperfusion injury and delayed graft function with C1 esterase inhibitor was associated with a lower incidence of graft failure.
RCT Entities:
BACKGROUND AND OBJECTIVES: Delayed graft function is related to ischemia-reperfusion injury and may be complement dependent. We previously reported from a randomized, placebo-controlled trial that treatment with C1 esterase inhibitor was associated with a shorter duration of delayed graft function and higher eGFR at 1 year. Here, we report longer-term outcomes from this trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a post hoc analysis of a phase 1/2, randomized, controlled trial enrolling 70 recipients of deceased donor kidney transplants at risk for delayed graft function (NCT02134314). Subjects were randomized to receive C1 esterase inhibitor 50 U/kg (n=35) or placebo (n=35) intraoperatively and at 24 hours. The cumulative incidence functions method was used to compare graft failure and death over 3.5 years. eGFR slopes were compared using a linear mixed effects model. RESULTS: Three deaths occurred among C1 esterase inhibitor-treated patients compared with none receiving placebo. Seven graft failures developed in the placebo group compared with one among C1 esterase inhibitor-treated recipients; the cumulative incidence of graft failure was lower over 3.5 years among C1 esterase inhibitor-treated recipients compared with placebo (P=0.03). Although no difference in eGFR slopes was observed between groups (P for group-time interaction =0.12), eGFR declined in placebo-treated recipients (-4 ml/min per 1.73 m2 per year; 95% confidence interval, -8 to -0.1) but was stable in C1 esterase inhibitor-treated patients (eGFR slope: 0.5 ml/min per 1.73 m2 per year; 95% confidence interval, -4 to 5). At 3.5 years, eGFR was 56 ml/min per 1.73 m2 (95% confidence interval, 42 to 70) in the C1 esterase inhibitor group versus 35 ml/min per 1.73 m2 (95% confidence interval, 21 to 48) in the placebo group, with an estimated mean eGFR difference of 21 ml/min per 1.73 m2 (95% confidence interval, 2 to 41 ml/min per 1.73 m2). CONCLUSIONS: Treatment of patients at risk for ischemia-reperfusion injury and delayed graft function with C1 esterase inhibitor was associated with a lower incidence of graft failure.
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; A R Wilk; A Robinson; J L Wainright; C R Haynes; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2018-01 Impact factor: 8.086
Authors: Giuseppe Castellano; Rita Melchiorre; Antonia Loverre; Pasquale Ditonno; Vincenzo Montinaro; Michele Rossini; Chiara Divella; Michele Battaglia; Giuseppe Lucarelli; Gennaro Annunziata; Silvano Palazzo; Francesco Paolo Selvaggi; Francesco Staffieri; Antonio Crovace; Mohamed R Daha; Maurice Mannesse; Sandra van Wetering; Francesco Paolo Schena; Giuseppe Grandaliano Journal: Am J Pathol Date: 2010-02-11 Impact factor: 4.307
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Juan S Danobeitia; Martynas Ziemelis; Xiaobo Ma; Laura J Zitur; Tiffany Zens; Peter J Chlebeck; Edwin S Van Amersfoort; Luis A Fernandez Journal: PLoS One Date: 2017-08-23 Impact factor: 3.240
Authors: Wilhelm J Schwaeble; Nicholas J Lynch; James E Clark; Michael Marber; Nilesh J Samani; Youssif Mohammed Ali; Thomas Dudler; Brian Parent; Karl Lhotta; Russell Wallis; Conrad A Farrar; Steven Sacks; Haekyung Lee; Ming Zhang; Daisuke Iwaki; Minoru Takahashi; Teizo Fujita; Clark E Tedford; Cordula M Stover Journal: Proc Natl Acad Sci U S A Date: 2011-04-18 Impact factor: 11.205
Authors: Jennifer D Motter; Kyle R Jackson; Jane J Long; Madeleine M Waldram; Babak J Orandi; Robert A Montgomery; Mark D Stegall; Stanley C Jordan; Enrico Benedetti; Ty B Dunn; Lloyd E Ratner; Sandip Kapur; Ronald P Pelletier; John P Roberts; Marc L Melcher; Pooja Singh; Debra L Sudan; Marc P Posner; Jose M El-Amm; Ron Shapiro; Matthew Cooper; Jennifer E Verbesey; George S Lipkowitz; Michael A Rees; Christopher L Marsh; Bashir R Sankari; David A Gerber; Jason R Wellen; Adel Bozorgzadeh; A Osama Gaber; Eliot C Heher; Francis L Weng; Arjang Djamali; J Harold Helderman; Beatrice P Concepcion; Kenneth L Brayman; Jose Oberholzer; Tomasz Kozlowski; Karina Covarrubias; Allan B Massie; Dorry L Segev; Jacqueline M Garonzik-Wang Journal: Am J Transplant Date: 2021-02-27 Impact factor: 8.086
Authors: Michael J Eerhart; Jose A Reyes; Casi L Blanton; Juan S Danobeitia; Peter J Chlebeck; Laura J Zitur; Megan Springer; Erzsebet Polyak; Jennifer Coonen; Saverio Capuano; Anthony M D'Alessandro; Jose Torrealba; Edwin van Amersfoort; Yolanda Ponstein; Cees van Kooten; William Burlingham; Jeremy Sullivan; Myron Pozniak; Weixiong Zhong; Yucel Yankol; Luis A Fernandez Journal: Transplantation Date: 2022-01-01 Impact factor: 5.385